Genmab P/E Ratio

Genmab's p/e ratio stands at 23.24. That is below the Healthcare sector average of 26.36. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Genmab sits lower the Healthcare benchmark (26.36) with a P/E ratio of 23.24. That is roughly 11.8% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

Whether 23.24 is attractive depends on Genmab's earnings outlook, competitive position, and how peers are valued. Investors typically ask: is growth accelerating, are margins stable, and is the multiple expanding or compressing over time? The history and comparison charts below are built for those checks.

The history chart shows how Genmab's P/E ratio evolved across reporting periods, while the comparison chart places GMAB next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, P/E ratio is commonly used to spot outliers. Genmab's reading of 23.24 (sector avg 26.36) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.